EntryPoint Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

EntryPoint Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$954K	Buy	95,427 +77,866	+443%	+$704K	0.23%	90
2026 Q1	$167K	Buy	17,561 +4,870	+38%	+$37.8K	0.05%	670
2025 Q4	$99K	Sell	12,691 -29,623	-70%	-$214K	0.04%	610
2025 Q3	$321K	Buy	42,314 +3,289	+8%	+$27.4K	0.12%	338
2025 Q2	$350K	Sell	39,025 -1,503	-4%	-$14K	0.18%	216
2025 Q1	$304K	Buy	+40,528	New	+$327K	0.14%	319
2024 Q4	–	Sell	-53,763	Closed	-$409K	–	729
2024 Q3	$409K	Sell	53,763 -5,062	-9%	-$38.5K	0.23%	116
2024 Q2	$364K	Buy	58,825 +16,146	+38%	+$89.1K	0.17%	108
2024 Q1	$217K	Buy	42,679 +37,275	+690%	+$210K	0.19%	92
2023 Q4	$32.4K	Buy	+5,404	New	+$31.3K	0.03%	895

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

EntryPoint Capital's BCRX Position: Q2 2026 in Review

EntryPoint Capital increased its BioCryst Pharmaceuticals (BCRX) stake by 443% in Q2 2026, buying an estimated $704K and bringing the position to 95,427 shares worth $954K. The position accounts for 0.23% of the portfolio, ranked #90.

EntryPoint Capital first reported a position in BCRX in Q4 2023 and has held it in 10 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

EntryPoint Capital held 95,427 shares of BioCryst Pharmaceuticals worth $954K as of Q2 2026.
EntryPoint Capital bought 77,866 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $704K.
BioCryst Pharmaceuticals made up 0.23% of EntryPoint Capital's portfolio in Q2 2026, its #90 holding.
EntryPoint Capital first reported a position in BioCryst Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.